Financial Statements Consolidated Statement of Comprehensive Income for the year ended 31December 2018 2017 2016 Notes $m $m $m Product Sales 1 21,049 20,152 21,319 Externalisation Revenue 1 1,041 2,313 1,683 Total Revenue 22,090 22,465 23,002 Cost of sales 4,936 4,318 4,126 Gross profit 17,154 18,147 18,876 Distribution costs 331 310 326 Research and development expense 2 5,932 5,757 5,890 Selling, general and administrative costs 2 10,031 10,233 9,413 Other operating income and expense 2 2,527 1,830 1,655 Operating profit 3,387 3,677 4,902 Finance income 3 138 113 67 Finance expense 3 1,419 1,508 1,384 Share of after tax losses in associates and joint ventures 10 113 55 33 Profit before tax 1,993 2,227 3,552 Taxation 4 57 641 146 Profit for the period 2,050 2,868 3,406 Other comprehensive income: Items that will not be reclassified to profit or loss: Remeasurement of the defined benefit pension liability 21 46 242 575 Net losses on equity investments measured at fair value through other comprehensive income 171 Fair value movements related to own credit risk on bonds designated as fair value through profit and loss 8 9 Tax on items that will not be reclassified to profit or loss 4 56 16 136 153 235 439 Items that may be reclassified subsequently to profit or loss: Foreign exchange arising on consolidation 22 450 536 1,050 Foreign exchange arising on designating borrowings in net investment hedges 22 520 505 591 Fair value movements on cash flow hedges 37 311 115 Fair value movements on cash flow hedges transferred to profit and loss 111 315 195 Fair value movements on derivatives designated in net investment hedges 22 8 48 4 Costs of hedging 54 Amortisation of loss on cash flow hedge 1 1 1 Net available for sale losses gains taken to equity 83 139 Tax on items that may be reclassified subsequently to profit or loss 4 51 33 86 906 874 1,339 Other comprehensive loss income for the period, net of tax 1,059 639 1,778 Total comprehensive income for the period 991 3,507 1,628 Profit attributable to: Owners of the Parent 2,155 3,001 3,499 Non-controlling interests 25 105 133 93 Total comprehensive income attributable to: Owners of the Parent 1,097 3,640 1,722 Non-controlling interests 25 106 133 94 Basic earnings per $0.25 Ordinary Share 5 $1.70 $2.37 $2.77 Diluted earnings per $0.25 Ordinary Share 5 $1.70 $2.37 $2.76 Weighted average number of Ordinary Shares in issue millions 5 1,267 1,266 1,265 Diluted weighted average number of Ordinary Shares in issue millions 5 1,267 1,267 1,266 Dividends declared and paid in the period 24 3,539 3,543 3,540 All activities were in respect of continuing operations.
$m means millions of US dollars.
AstraZeneca Annual Report & Form 20-F Information 2018 Consolidated Statements 149 Consolidated Statement of Financial Position at 31December 2018 2017 2016 Notes $m $m $m Assets Non-current assets Property, plant and equipment 7 7,421 7,615 6,848 Goodwill 8 11,707 11,825 11,658 Intangible assets 9 21,959 26,188 27,586 Investments in associates and joint ventures 10 89 103 99 Other investments 11 833 933 727 Derivative financial instruments 12 157 504 343 Other receivables 13 515 847 901 Deferred tax assets 4 2,379 2,189 1,102 45,060 50,204 49,264 Current assets Inventories 14 2,890 3,035 2,334 Trade and other receivables 15 5,574 5,009 4,573 Other investments 11 849 1,230 884 Derivative financial instruments 12 258 28 27 Income tax receivable 207 524 426 Cash and cash equivalents 16 4,831 3,324 5,018 Assets held for sale 17 982 15,591 13,150 13,262 Total assets 60,651 63,354 62,526 Liabilities Current liabilities Interest-bearing loans and borrowings 18 1,754 2,247 2,307 Trade and other payables 19 12,841 11,641 10,486 Derivative financial instruments 12 27 24 18 Provisions 20 506 1,121 1,065 Income tax payable 1,164 1,350 1,380 16,292 16,383 15,256 Non-current liabilities Interest-bearing loans and borrowings 18 17,359 15,560 14,501 Derivative financial instruments 12 4 4 117 Deferred tax liabilities 4 3,286 3,995 3,956 Retirement benefit obligations 21 2,511 2,583 2,186 Provisions 20 385 347 353 Other payables 19 6,770 7,840 9,488 30,315 30,329 30,601 Total liabilities 46,607 46,712 45,857 Net assets 14,044 16,642 16,669 Equity Capital and reserves attributable to equity holders of the Company Share capital 23 317 317 316 Share premium account 4,427 4,393 4,351 Capital redemption reserve 153 153 153 Merger reserve 448 448 448 Other reserves 22 1,440 1,428 1,446 Retained earnings 22 5,683 8,221 8,140 12,468 14,960 14,854 Non-controlling interests 25 1,576 1,682 1,815 Total equity 14,044 16,642 16,669 The Financial Statements from pages 149 to 204 were approved by the Board and were signed on its behalf by Pascal Soriot Marc Dunoyer Director Director 14February 2019 150 AstraZeneca Annual Report & Form 20-F Information 2018 Financial Statements Financial Statements Consolidated Statement of Changes in Equity for the year ended 31December Share Capital Total NonShare premium redemption Merger Other Retained attributable controlling Total capital account reserve reserve reserves earnings toowners interests equity $m $m $m $m $m $m $m $m $m At 1January 2016 316 4,304 153 448 1,435 11,834 18,490 19 18,509 Profit for the period 3,499 3,499 93 3,406 Other comprehensive loss 1,777 1,777 1 1,778 1 Transfer to other reserves 11 11 Transactions with owners Dividends 3,540 3,540 3,540 Dividends paid by subsidiary to non-controlling interest 13 13 Acerta Pharma put option Note 25 1,825 1,825 1,825 Changes in non-controlling interest Note 25 1,903 1,903 Issue of Ordinary Shares 47 47 47 Share-based payments charge for the period Note 28 241 241 241 Settlement of share plan awards 281 281 281 Net movement 47 11 3,694 3,636 1,796 1,840 At 31December 2016 316 4,351 153 448 1,446 8,140 14,854 1,815 16,669 Profit for the period 3,001 3,001 133 2,868 Other comprehensive income 639 639 639 1 Transfer to other reserves 18 18 Transactions with owners Dividends 3,543 3,543 3,543 Issue of Ordinary Shares 1 42 43 43 Share-based payments charge for the period Note 28 220 220 220 Settlement of share plan awards 254 254 254 Net movement 1 42 18 81 106 133 27 At 31December 2017 317 4,393 153 448 1,428 8,221 14,960 1,682 16,642 2 Adoption of new accounting standards 91 91 91 Profit for the period 2,155 2,155 105 2,050 3 Other comprehensive loss 1,058 1,058 1 1,059 1 Transfer to other reserves 12 12 Transactions with owners Dividends 3,539 3,539 3,539 Issue of Ordinary Shares 34 34 34 Share-based payments charge for the period Note 28 219 219 219 Settlement of share plan awards 212 212 212 Net movement 34 12 2,538 2,492 106 2,598 At 31December 2018 317 4,427 153 448 1,440 5,683 12,468 1,576 14,044 1 Amounts charged or credited to other reserves relate to exchange adjustments arising on goodwill.
2 The Group adopted IFRS 15 Revenue from Contracts with Customers from 1 January 2018.
3 Included within Other comprehensive loss of $1,059m is a charge of $54m relating to Costs of hedging.
AstraZeneca Annual Report & Form 20-F Information 2018 Consolidated Statements 151 Consolidated Statement of Cash Flows for the year ended 31December 2018 2017 2016 Notes $m $m $m Cash flows from operating activities Profit before tax 1,993 2,227 3,552 Finance income and expense 3 1,281 1,395 1,317 Share of after tax losses of associates and joint ventures 10 113 55 33 Depreciation, amortisation and impairment 3,753 3,036 2,357 Increase decrease in trade and other receivables 523 83 1,610 Increase in inventories 13 548 343 Decrease increase in trade and other payables and provisions 103 415 341 Gains on disposal of intangible assets 2 1,885 1,518 1,301 Fair value movements on contingent consideration arising from business combinations 19 495 109 1,158 Non-cash and other movements 16 290 524 492 Cash generated from operations 3,831 4,730 5,234 Interest paid 676 698 677 Tax paid 537 454 412 Net cash inflow from operating activities 2,618 3,578 4,145 Cash flows from investing activities Non-contingent payments on business combinations 1,450 2,564 Payment of contingent consideration from business combinations 19 349 434 293 Purchase of property, plant and equipment 1,043 1,326 1,446 Disposal of property, plant and equipment 12 83 82 Purchase of intangible assets 328 294 868 Disposal of intangible assets 2,338 1,376 1,427 Purchase of non-current asset investments 102 96 230 Disposal of non-current asset investments 24 70 3 Movement in short-term investments and fixed deposits 405 345 166 Payments to joint ventures 10 187 76 41 Interest received 193 164 140 Payments made by subsidiaries to non-controlling interests 13 Net cash inflow outflow from investing activities 963 2,328 3,969 Net cash inflow before financing activities 3,581 1,250 176 Cash flows from financing activities Proceeds from issue of share capital 34 43 47 Issue of loans 2,971 1,988 2,491 Repayment of loans 1,400 1,750 Dividends paid 3,484 3,519 3,561 Hedge contracts relating to dividend payments 67 20 18 Repayment of obligations under finance leases 14 16 Movement in short-term borrowings 98 336 303 Net cash outflow from financing activities 2,044 2,936 1,324 Net increase decrease in Cash and cash equivalents in the period 1,537 1,686 1,148 Cash and cash equivalents at the beginning of the period 3,172 4,924 6,051 Exchange rate effects 38 66 21 Cash and cash equivalents at the end of the period 16 4,671 3,172 4,924 152 AstraZeneca Annual Report & Form 20-F Information 2018 Financial Statements
